Victory Capital Management
TPTX

Victory Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Victory Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,002
Closed -$452K – 2832
2022
Q2 		$452K Sell
6,002
-19,551
-77% -$869K ﹤0.01% 2101
2022
Q1 		$752K Buy
25,553
+19,290
+308% +$648K ﹤0.01% 1949
2021
Q4 		$299K Sell
6,263
-260
-4% -$11.6K ﹤0.01% 2385
2021
Q3 		$433K Sell
6,523
-1,870
-22% -$133K ﹤0.01% 2244
2021
Q2 		$655K Sell
8,393
-456,440
-98% -$33.7M ﹤0.01% 2064
2021
Q1 		$44M Buy
464,833
+395,149
+567% +$47M 0.05% 599
2020
Q4 		$8.49M Buy
69,684
+34,969
+101% +$3.83M 0.01% 1131
2020
Q3 		$3.03M Sell
34,715
-1,265
-4% -$88.1K ﹤0.01% 1313
2020
Q2 		$2.32M Sell
35,980
-178,218
-83% -$10.3M ﹤0.01% 1384
2020
Q1 		$9.57M Buy
214,198
+104,335
+95% +$5.54M 0.01% 1098
2019
Q4 		$6.84M Buy
109,863
+107,728
+5,046% +$5.13M 0.01% 1110
2019
Q3 		$80K Buy
+2,135
New +$92.9K ﹤0.01% 2509

Victory Capital Management's TPTX Position: Q3 2022 in Review

Victory Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 6,002 shares — an estimated $452K sold.

Victory Capital Management first reported a position in TPTX in Q3 2019 and held it in 12 quarters. The position peaked at $44M in Q1 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Victory Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Victory Capital Management sold 6,002 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $452K.
  • Victory Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 12 quarters.
  • Victory Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $44M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Victory Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.